Macrocyclic antibiotic (narrow-spectrum)
Fidaxomicin
Brand names: Dificlir
Adult dose
Dose: 200mg BD for 10 days
Route: PO
Frequency: BD
Clinical pearls
- C. difficile infection — recurrence rate lower than vancomycin
- NICE: first-line for first or recurrent CDI per current guidance
Contraindications
- Hypersensitivity
Side effects
- Nausea
- Vomiting
- Constipation
- Rash
Interactions
- P-gp inhibitors (ciclosporin) — minor
Monitoring
- Resolution of diarrhoea
Reference: BNF; NICE NG199; UK CDI guidelines; https://bnf.nice.org.uk/drugs/fidaxomicin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Clostridioides difficile Severity Grading · Gastrointestinal Infection
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Primary Angle Closure Disease Spectrum (PACS / PAC / PACG) · Glaucoma
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023